NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/04/2024
Voltar para busca
Dado oficial do USPTO
ORSHINA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
ORSHINA
ST13
US500000097318817Classe
1, 5, 42, 44
Pedido
97318817
Registro
7342346
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
18
Atualização mais recente
02/04/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42, 44
Data de depósito
18/03/2022
Data de registro
02/04/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
02/04/2024
Última transação
02/04/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Foreign priority
Código do desenho
4
Tipo de titular
99
Localização do titular
Neuherberg, DE
Examinador
CANTONE, KERI H
Unidade examinadora
L40
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Representantes
Ryan D. Artis RIVERSIDE LAW LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals for use in industry and sciencein particular reagents for labelling of biomoleculesreagents for tagging of biomolecules; reagents for non-medical purposes for visualization or detection of biomolecules; reagents for non-medical purposes for tagging of chemical entities or chemical molecules; reagents for non-medical purposes for generation of molecular constructstransfection reagentsreagents for gene editing; reagents for non-medical purposes for investigations in relation to tissue disorders; reagents for non-medical purposes for investigations in relation to fibrosis; reagents for non-medical purposes for investigations in relation to inflammatory disorders; diagnostic reagentsnot for medical or veterinary purposes; chemical reagent mixtures in kit formother than for medical or veterinary use; Kits comprising reagents for use in scientific researchin particular kits for labelling of biomolecules; kits for non-medical purposes for tagging of biomolecules comprising reagents for tagging of biomolecules; kits for non-medical purposes for visualization or detection of biomolecules comprising reagents for visualization or detection of biomolecules; kits for non-medical purposes for generation of molecular constructs comprising reagents for generation of molecular constructs; transfection kits comprising reagents for transfection of cells; kits for non-medical purposes for gene editing comprising reagents for gene editing; kits for non-medical purposes for investigations in relation to tissue disorders comprising reagents for investigations in relation to tissue disorders; kits for non-medical purposes for investigations in relation to fibrosis comprising reagents for investigations of fibrosis; kits for non-medical purposes for investigations in relation to inflammatory disorders comprising reagents for investigations of inflammatory disorders; diagnostic kits comprising diagnostic reagents for scientific or research use not for medical and veterinary purposes
Classe 5
Pharmaceuticalsin particular pharmaceuticals for treating fibrosispharmaceuticals for treating lung diseasespharmaceuticals for treating inflammatory disorderspharmaceuticals for treating scars and scar formationpharmaceuticals for promoting tissue repair and/or tissue regenerationpharmaceuticals for wound healingwherein all aforementioned pharmaceuticals include small chemical moleculespeptidesproteinsnucleic acidscellular products and gene therapy products; Diagnostic reagentsfor medical and veterinary purposes
Classe 42
Scientific and industrial research in particular in the biochemicaldiagnostic or pharmaceutical fields; Biochemical and pharmaceutical laboratory servicesin particular in the field of discovery and development of drugs for treating fibrosislung diseasesscarsdrugs for preventing scar formation or drugs for wound healingin the field of discovery of drugs for promoting tissue repair and/or tissue regeneration; Chemical and biochemical analysis of active ingredients in the field of drugs for treating fibrosislung diseasesscarsin the field of drugs for preventing scar formation or drugs for wound healingin the field of drugs for promoting tissue repair and/or tissue regeneration; Scientific research consultancyin particular with respect to drug discovery methodologies and systems for drug discovery and with respect to drug development methodologies and systems for drug development
Classe 44
Diagnosis and treatment of fibrosislung diseasesscars or scar formation; Diagnosis and healing of wound; Diagnosis and healing being medical services of wounds; Medical treatment being tissue repair and/or tissue regeneration for treatment of inflammatory conditions; Treatment prediction and diagnostics in the field of medicine and veterinary medicine
Publicações
Histórico de despachos e eventos da marca no USPTO.
18 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
02/04/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
16/01/2024
PUBO
PUBLISHED FOR OPPOSITION
16/01/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
27/12/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/12/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/12/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/12/2023
ALIE
ASSIGNED TO LIE
01/12/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
28/06/2023
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
29/03/2023
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
29/03/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/01/2023
GNRT
NON-FINAL ACTION E-MAILED
06/01/2023
CNRT
NON-FINAL ACTION WRITTEN
06/01/2023
DOCK
ASSIGNED TO EXAMINER
30/12/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
23/03/2022
NWAP
NEW APPLICATION ENTERED
22/03/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ORSHINA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.